Details of the Drug

General Information of Drug (ID: DMM4U9G)

Drug Name
R0-93877
Synonyms
Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN]
Indication
Disease Entry ICD 11 Status REF
Constipation DD91.1 Approved [1]
Irritable bowel syndrome DD91.0 Approved [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 367.9
Logarithm of the Partition Coefficient (xlogp) 2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 64000-762000 mcgday/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 3800-45000 mcg/L [3]
Bioavailability
The bioavailability of drug is 66% [3]
Clearance
The renal clearance of drug is 17 L/h [4]
Elimination
Prucalopride is mainly excreted by the urine, representing 84% of the administered dose while only 13% of the dose is recovered in feces [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 - 20 hours [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.7% [5]
Vd
The volume of distribution (Vd) of drug is 623 L [4]
Chemical Identifiers
Formula
C18H26ClN3O3
IUPAC Name
4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide
Canonical SMILES
COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl
InChI
InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)
InChIKey
ZPMNHBXQOOVQJL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3052762
ChEBI ID
CHEBI:135552
CAS Number
179474-81-8
DrugBank ID
DB06480
TTD ID
D04QSJ
VARIDT ID
DR00187
ACDINA ID
D01369
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Agonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Constipation
ICD Disease Classification DD91.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 4 receptor (HTR4) DTT HTR4 1.70E-02 -0.17 -0.32
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from R0-93877 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Gilteritinib DMTI0ZO Moderate Decreased clearance of R0-93877 due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [8]
Erdafitinib DMI782S Moderate Decreased clearance of R0-93877 due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [9]
Umeclidinium DM4E8O9 Moderate Antagonize the effect of R0-93877 when combined with Umeclidinium. Chronic obstructive pulmonary disease [CA22] [10]
Revefenacin DMMP5SI Moderate Antagonize the effect of R0-93877 when combined with Revefenacin. Chronic obstructive pulmonary disease [CA22] [10]
Levonorgestrel DM1DP7T Moderate Altered absorption of R0-93877 caused by Levonorgestrel. Contraceptive management [QA21] [8]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered absorption of R0-93877 caused by Oestradiol valerate and dienogest. Endometriosis [GA10] [8]
Belladonna DM2RBWK Moderate Antagonize the effect of R0-93877 when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [10]
Lasmiditan DMXLVDT Moderate Decreased clearance of R0-93877 due to the transporter inhibition by Lasmiditan. Migraine [8A80] [11]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of R0-93877 when combined with Methylscopolamine. Peptic ulcer [DA61] [10]
⏷ Show the Full List of 9 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Colcothar yellow E00436 518696 Colorant
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Prucalopride 2 mg tablet 2 mg Tablet Oral
Prucalopride 1 mg tablet 1 mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. N Engl J Med. 2017 Feb 23;376(8):717-728. doi: 10.1056/NEJMoa1605767.
4 A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers. Clin Ther. 2016 Sep;38(9):2106-15. doi: 10.1016/j.clinthera.2016.08.003. Epub 2016 Sep 7.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
7 Resolor, INN-prucalopride
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
10 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
11 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.